BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its drug IGALMI. https://t.co/6KNkAMU2dq

📈 Pre-Market Movers 🚀 (Biggest Gainers) 1️⃣ $CMRX (Chimerix) +69.35% 📊 $8.40 🔥 Vol: 47.83M | Float: 85.16M 2️⃣ $BTAI (BioXcel Therapeutics) +15.92% 📊 $3.13 🚀 Vol: 3.88M | Float: 2.58M 3️⃣ $ZVSA (ZyVersa Therapeutics) +15.74% 📊 $1.25 🚀 Vol: 3.00M | Float: 2.50M 4️⃣ $OPFI

$BTAI 07:14 on Jan. 12 2026 BioXcel Therapeutics Plans To Submit sNDA In January Seeking FDA's Approval Of IGALMI For At-Home Use In Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia #tradeideas

$BTAI - BioXcel Therapeutics, Inc. - 10K - Updated Risk Factors BTAI's 2025 risk factors highlight a strategic shift back to R&D, liquidity concerns, Nasdaq delisting risk, FDA compliance challenges, and increased legal and IP litigation threats. Workforce cuts and market

$BTAI Management Change: On January 12, 2026, BioXcel Therapeutics, Inc. announced that Mark Pavao will be the Interim Chief Commercial Officer to aid in launching IGALMI for at-home use, and plans to file a supplemental New Drug Application this month to seek FDA approval.

BioXcel Therapeutics firma koncentrująca się na opracowaniu leków przy pomocy AI.💊🤖 Odnosi coraz większe sukcesy np. z preparatem do leczenia pobudzenia związanego z schizofrenią i dwubiegunówką. 🧬 Po ogłoszeniu udziału w konferencji CG. $BTAI wzrasta o ponad +50% 🚀 #XTB

$BTAI - BioXcel Therapeutics 🔹Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial 🔹For Agitation Associated with Bipolar Disorders or Schizophrenia 🔹Fast Track Designation granted by FDA 🔹Low Float/ OS near 18m shares 👆

$BTAI - BioXcel Therapeutics 🔹Announces Positive Results from Correlation Study 🔹Supporting SERENITY At-Home Exploratory Efficacy Outcomes 🔹Planned sNDA submission in Q1 2026 🔹Low Float/ OS near 20m shares 👆 0% PreM/ $2.60

$BTAI Research Presentation: On November 10, 2025, BioXcel Therapeutics, Inc. announced that Dr. Leslie Citrome presented a poster on their Phase 3 study of BXCL501 at a conference on November 7, 2025. https://t.co/kgEdUVJ4Ps

Most Traded Tickers in pre-market today: $BTAI - H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI) $SGBX - Safe & Green Holdings Entered Into Non-Binding Intent To Acquire Rock Springs Energy For ~$35M $PHGE - BiomX Inc. 13G Filing Shows Morgan Stanley Reports

After⏲Hours 4:00 $BTAI - BioXcel Therapeutics 🔹To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial 🔹For Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025 🔹Low Float/ OS near 16m shares

🧠 A differentiated approach to neuroscience. 🧬 @BioXcel_Tx is utilizing artificial intelligence to develop medicines aimed to transform patients’ lives. 🎊 Proud to be your exchange partner, $BTAI!

$BTAI: FDA GREEN LIGHT = SHORT SQUEEZE ALERT BioXcel ($BTAI) just got a MAJOR catalyst – FDA cleared the site inspection for its Phase 3 TRANQUILITY II trial for treating Alzheimer's-related agitation. This is a huge validation for the company's drug development & data

$BTAI - BioXcel Therapeutics 🔹Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial 🔹For Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia 🔹BXCL501 received Fast Track Designation from FDA 🔹Low Float/ OS near 15M shares 👇

$BTAI 🚀 +19% 📈 🔹 BioXcel = AI-driven biopharma focused on neuro + immuno-oncology 🧠 🔹 Catalyst: company says it plans to submit an sNDA this month for at-home use of IGALMI® (acute agitation in bipolar/schizophrenia) 📝 🔹 At-home label expansion = bigger addressable market

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease $BTAI

Most Traded Tickers in pre-market today: $MWYN - No catalyst found today $BTAI - BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia $NAMM -

Most Traded Tickers in pre-market today: $PBM - Corporate Update, August 2025 https://t.co/oDDPRFuLg3 $COMM - Amphenol To Acquire CommScope's Connectivity And Cable Solutions Business For10.5B In Cash $BTAI - H.C. Wainwright Reiterates Buy Rating on BioXcel Therapeutics (BTAI)

🟢ا $BTAI 🔸ا BioXcel Therapeutics تعتزم تقديم طلب ترخيص إضافي (sNDA) هذا الشهر للحصول على موافقة إدارة الغذاء والدواء الأمريكية (FDA) على الاستخدام المنزلي لعقار #IGALMI® والذي يعالج الهياج المصاحب لاضطراب ثنائي القطب من النوع الأول أو الثاني أو الفصام علماً بأن الدواء قد حصل